Prevalence and factors associated with Intestinal parasitosis among adults with diabetes mellitus attending a tertiary care facility in Northern Uganda: A hospital-based cross-sectional study Authors: Hillary Ngolobe, Martin Kugonza, Phillip Nkwatsibwe, Anthony Kato, Donald Otika, Morrish Obol Okello, Daniel S. Ebbs, Felix Bongomin, Alqeer Aliyo Ali, Alqeer Aliyo Ali, Alqeer Aliyo Ali, Alqeer Aliyo Ali Published: 2025 ABSTRACT Intestinal parasitosis (IP) constitutes a significant public health problem in developing countries, where more than three billion people worldwide are infected with one or more intestinal parasites. Diabetes mellitus (DM) is associated with an increased risk of acquiring IP. This study aimed to determine the prevalence and associated factors of IP among patients with DM attending Gulu Regional Referral Hospital (GRRH) in Northern Uganda. A hospital-based cross-sectional study was conducted using a semi-structured questionnaire and stool sample analysis. Descriptive statistics were used to summarize patient characteristics, and bivariate logistic regression was performed to assess associated factors of IP among DM patients attending GRRH. Out of the 267 eligible patients, 201 participated, indicating a response rate of 75.3%. The majority were female (68.2%, n = 137), with a mean age of 55.8 ± 12.8 years. Almost all participants had type 2 diabetes mellitus (99.0%, n = 199), with a mean duration of 7.0 ± 6.8 years and a mean fasting blood glucose of 11.9 ± 6.4 mmol/L. The prevalence of intestinal parasitosis was 19.4% (39/201). Entamoeba coli, a non-pathogenic commensal, accounted for 35 cases (89.7%), while the four pathogenic parasites; Hymenolepis nana, Giardia duodenalis, Entamoeba histolytica, and Iodamoeba buetschlii, were each identified in one case (2.6%). Patients who did not seek medical attention for the abdominal symptoms were three times more likely to have intestinal parasitoses (cOR =3.0, 95% CI: 1.18–7.53, P = 0.014). The notable prevalence of IP among patients with DM suggests heightened susceptibility in this population, which may adversely affect their quality of life. Routine screening for intestinal parasites is therefore recommended for diabetic patients. 1. Introduction Intestinal parasitosis (IP) constitutes a critical problem of public health importance, especially in developing countries. It is estimated that globally, approximately 3.5 billion people are infected by various types of IPs, and over 200,000 deaths are reported annually [1]. It has been highlighted that IPs are one of the major causes of digestive disorders (such as diarrhea, nausea, and vomiting), chronic malabsorption and malnutrition, and failure to thrive, especially among high-risk groups, namely, children, pregnant women, and immunocompromised patients [2–4]. Personal hygiene, environmental sanitation, level of education, occupation, and overcrowding are probable factors that predispose individuals to intestinal parasitic infections [5] Diabetes Mellitus (DM) is a chronic metabolic disease affecting over 589 million adults in 2024 and expected to rise to 853 million by 2050 [6]. DM is characterized by chronic hyperglycemia and is due to either deficient insulin release or reduced response to insulin [7]. DM increases the risk of infections, and in particular intestinal parasites, due to impaired innate and adaptive immune responses [8]. A recent systematic review found that intestinal parasites were more prevalent in patients with DM compared to those without [9], and therefore stands out as a risk factor for intestinal parasites The global prevalence of intestinal parasites among patients with DM has been estimated to be 24.4% [9] with 31% in Africa [10]. Country-specific studies have reported a prevalence of 19.5% in Ethiopia [11], 12.5% in Ghana [12] and 18.7% in Nigeria [13]. Uganda’s prevalence of IP among patients with diabetes mellitus has not been studied yet. Most studies conducted in Uganda on intestinal parasitosis have focused on children, considering them as at higher risk than the other population groups [14,15]. However, a previous study conducted in Ethiopia highlighted that adults who are immunocompromised are also at risk of getting intestinal parasitic infections, underscoring the need for more data to be obtained among these populations [16]. Our study is timely to add to the literature on intestinal parasitosis in Uganda, particularly among the adult population that is immunocompromised.. Therefore, our study aims to assess the prevalence and associated factors of IP among DM patients attending Gulu Regional Referral Hospital (GRRH) in Northern Uganda. 2. Methods 2.1. Study design and setting This was a hospital-based cross-sectional study utilizing a quantitative approach, conducted from the 28th of October 2024 to the 3rd of March 2025. This study was designed in accordance with the STROBE guidelines for cross-sectional studies. It was carried out at the DM clinic of GRRH, which operates every Monday with an attendance of over 50 patients. 2.2. Study population, Inclusion and exclusion criteria Adults receiving care from the diabetic clinic at GRRH were targeted. Patients aged 18 years and above, with a physician-confirmed diagnosis of DM, and who provided a written informed consent were included. Patients who received anti-helminth drugs in the past 2 weeks, those with hyperglycemic crisis, and those who had constipation were excluded. 2.3. Sample size determination and sampling procedure The sample size (n) was calculated using Cochran’s formula n = Z2*P(1-P)/d2: considering z = 1.96 (for a 95% confidence interval), p = estimated prevalence, 19.5% [11], and d = 0.05 (margin of error at 5%)an expected response rate of 90%, the sample size was 267. A convenient sampling technique was employed, and eligible participants were chosen consecutively. This sampling technique was used because of the difficulty in accessing study participants and the limited time available for conducting data collection. 2.4. Research instrument and Data collection An interviewer-administered semi-structured questionnaire was used to collect data on socio-demographics, as well as factors associated with STHI. The questionnaire was adapted based on a previous study on intestinal parasites among patients with DM [11]. Participants were interviewed after consultation with the physician when they came for routine care at the DM clinic of GRRH. The interviews were conducted in the clinical room provided by the hospital to ensure confidentiality. A stool sample was then obtained from each of the participants and taken for analysis within 4 hours of sample collection. Two [2] thick smears were prepared for analysis using both the Kato Katz and Odongo-Aginya stains. The stool analysis was performed by 1 laboratory technician and a professor of parasitology. 2.5. Data management and analysis Completed questionnaires were securely stored and then entered into Excel before being exported to Stata version 18 for analysis. Descriptive statistics were performed, and categorical variables were summarized as frequencies and percentages. Numerical data were assessed for normality using the Shapiro-Wilk test and then summarized as means and standard deviations or median and interquartile range, accordingly. 2.6. Ethical considerations Ethical approval was obtained from Gulu University Research Ethics Committee (GUREC, GUREC-2024–926). Initial approval was granted on 29/09/2024, and data collection commenced on 28/10/2024. Amendments were made, and the approval for the amendments was on 30/05/2025Administrative clearance was obtained from GRRH Institutional Review Board.. Written informed consent was obtained, and the purpose of the study was explained to the study participants. The participants were informed of their right to withdraw from the study at any time. All data collected was kept confidential and anonymous. All the other ethical principles outlined in the Declaration of Helsinki were observed. 3. Results 3.1. Study enrolment A total of 252 patients were screened to participate in the study. Of these, 51 were excluded. Those excluded were due to: constipation and could therefore not provide a stool sample (29), recent use of anthelmintics and therefore there is a possibility of eradicating the helminths [20], and those in a hyperglycemic crisis and were therefore unstable to participate in the study [2]. Eventually, 201 participants participated in the study, indicating a 75.3% (n = 201/267) response rate Fig 1 Study enrolment diagram. 3.2. Sociodemographic characteristics of people with DM attending GRRH The mean age of participants was 55.8 ± 12.8 years, with a majority being female (n = 137, 68.2%). Most were of Acholi ethnicity (n = 178, 88.6%) and married (n = 143, 71.1%). Educational attainment was low, with over half having only primary education (n = 106, 52.7%) and 20.9% (n = 42) having no formal education. Slightly more participants resided in urban areas (n = 105, 52.2%) than rural areas (n = 96, 47.8%). The majority were self-employed (n = 182, 90.5%). Christianity was the dominant religion (n = 197, 98.0%), with Catholics forming the largest denomination (n = 114, 56.7%), Table 1 10.1371/journal.pone.0338774.t001Table 1Socio-demographic characteristics of people with DM attending GRRH.Variable (N=201)FrequencyPercentAge, mean ± SD, years55.812.8Gender Female13768.2 Male6431.8 Tribe Acholi17888.6 Others*2311.4Marital status Married14371.1 Widowed4220.9 Divorced105.0 Single63.0Education level No formal education4220.9 Primary10652.7 Secondary3617.9 Tertiary178.5Residence Rural9647.8 Urban10552.2Occupation Civil servants73.5 Self-employed18290.5 Unemployed126.0Religion Christian19798.0 Catholic11456.7 Born again4321. 4 Anglican3919.4 SDA10.5 Moslem42.0*Other tribes: Langi (13, 6.5%), Alur (5, 2.5%), Lugbara, Muganda, Mukiga, munyankole, munyoro (1 each, 0.5%) Socio-demographic characteristics of people with DM attending GRRH. *Other tribes: Langi (13, 6.5%), Alur (5, 2.5%), Lugbara, Muganda, Mukiga, munyankole, munyoro (1 each, 0.5%) 3.3. Clinical characteristics of people with DM attending GRRH Almost all participants had type 2 diabetes (n = 199, 99.0%), with a mean duration of 7.0 ± 6.8 years and a mean fasting blood sugar of 11.9 ± 6.4 mmol/L. Glycaemic control was poor, with most having uncontrolled fasting plasma glucose (n = 148, 73.6%). Diabetes-related complications were reported in 86.6% (n = 174), predominantly neuropathy (n = 156, 77.6%) and retinopathy (n = 100, 49.8%). Most participants were on oral anti-hyperglycaemic medications alone (n = 172, 85.6%). Co-morbidities were present in 73.1% (n = 147), primarily hypertension (n = 141, 70.1%), Table 2. 10.1371/journal.pone.0338774.t002Table 2Clinical characteristics of people with DM attending GRRH.Variable, N=201FrequencyPercentType of diabetes Type 121.0 Type 219999.0 Duration of diabetes, mean ± SD; years7.06.8 Fasting blood sugar, mean ± SD; mmol/L11.96.4Glycaemic control Controlled5326.4 Uncontrolled14873.6Diabetes complications Yes17486.6 No2713.4Complications of diabetes (n=174) Neuropathy15677.6 Retinopathy10049.8 Nephropathy94.5Current anti-hyperglycaemic therapy All oral medicines17285.6 Insulin and oral medicines178.5 Insulin alone126.0Co-morbidities Yes14773.1 No5426.9Proportions with co-morbidities (n=147) Hypertension14170.1 HIV63.0 Peptic ulcer disease31.5 Viral hepatitis21.0 Chronic heart disease10.5 Clinical characteristics of people with DM attending GRRH. 3.4. Risk factors for intestinal parasitosis infection among people with DM attending GRRH A family history of intestinal parasitosis was reported by 12.9% (n = 26). Most participants often used footwear outdoors (n = 149, 74.1%) and practiced regular handwashing before eating (n = 195, 97.0%). Pet ownership was common (n = 136, 67.7%). The main sources of water were boreholes (n = 117, 58.2%) and natural sources (n = 42, 20.9%), while most used pit latrines for faecal disposal (n = 178, 88.6%). A high proportion reported current gastrointestinal symptoms (n = 146, 72.6%), predominantly abdominal pain (n = 120, 59.7%) and gastrointestinal upset (n = 93, 46.3%), though only 31.8% (n = 64) had sought physician consultation, with few symptoms linked to intestinal parasitosis (n = 4, 2.0%), Table 3. 10.1371/journal.pone.0338774.t003Table 3Risk factors for intestinal parasitosis among people with DM attending GRRH.Variable, N=201FrequencyPercentFamily history of intestinal parasitosis, yes2612.9Use of footwear while walking outdoors Never21.0 Rarely5024.9 Often14974.1 Pet animals at home, yes13667.7Handwashing before eating Rarely10.5 Sometimes52.5 Always19597.0Water source Bore hole11758.2 Natural water sources4220.9 Pipped water3215.9 Mixed sources105.0Human faecal disposal Pit latrines17888.6 Toilet2311.4Current gastrointestinal symptoms Symptomatic14672.6 Asymptomatic5527.4Proportion of symptoms, n=146 Abdominal pain12059.7 Nausea, vomiting and diarrhoea9346.3 Weightless2612.9 Physician consultation for gastrointestinal symptom, n=146; yes6431.8 Symptom linked to IP42.0 Risk factors for intestinal parasitosis among people with DM attending GRRH. 3.5. Prevalence of intestinal parasitosis among people with DM attending GRRH Of the 201 participants, 39 (19.4%) were found to have intestinal parasitosis. Entamoeba coli, a non-pathogenic commensal, constituted the majority (35 cases, 89.7%), while the four pathogenic parasites-. Hymenolepis nana, Giardia duodenalis, Entamoeba histolytica, and Iodamoeba buetschlii were each identified in one case (2.6%). Figs 2 and 3 Doughnut pie chart showing the distribution of intestinal parasitosis. Images of identified parasites. 3.6. Factors associated with intestinal parasitosis among patients with DM attending GRRH We performed simple logistic regression at bivariate analysis and a p < 0.05 was considered statistically significant. Only one factor was found to be statistically significant; patients who did not seek medical attention for the abdominal symptoms were three (3) times more likely to have intestinal parasites (cOR =3.0, 95 CI: 1.18–7.53, P = 0.014.) Table 4. 10.1371/journal.pone.0338774.t004Table 4Shows analysis of factors associated with intestinal parasitosis among DM patients.VariableIntestinal ParasitescOR (95% CI)P-valueNo (n=162)Yes (n=39)Age1.0 (0.97–1.03)0.928Fasting Blood Sugar1.0 (0.98–1.09)0.256Gender Female111 (68.5)26 (66.7)1 Male51 (31.5)13 (33.3)0.9 (0.44–1.93)0.824Tribe Others*20 (12.3)3 (7.7)1 Acholi142 (87.7)36 (92.3)1.7 (0.48–6.00)0.392Education Level Primary85 (52.5)21 (53.8)1 No formal32 (19.8)10 (25.6)1.3 (0.54–2.98)0.379 Secondary29 (17.9)7 (17.9)1.0 (0.38–2.54) Tertiary16 (9.9)1 (2.6)0.3 (0.03–2.02)Residence Rural78 (48.1)18 (46.2)1 Urban84 (51.9)21 (53.8)1.1 (0.54–2.18)0.823Occupation Civil-servant6 (3.7)1 (2.6)10.837 Self-employed147 (90.7)35 (89.7)1.4 (0.17–12.25) Unemployed9 (5.6)3 (7.7)2 (0.17-24.07)Blood Sugar Control Controlled44 (27.2)9 (23.1)1 Uncontrolled118 (72.8)30 (76.9)1.2 (0.55–2.83)0.599Diabetic Complications No22 (13.6)5 (12.8)10.900 Yes140 (86.4)34 (87.2)0.9 (0.33–2.65)Comorbidities No45 (27.8)9 (23.1)1 Yes117 (72.2)30 (76.9)1.3 (0.56–2.91)0.547Family History of IP No141 (87.0)34 (87.2)1 Yes21 (13.0)5 (12.8)1.0 (0.36–2.88)0.981Pets at home No52 (32.1)13 (33.3)1 Yes110 (67.9)26 (66.7)1.1 (0.50–2.22)0.883Water Source Borehole96 (59.3)21 (53.8)1 Natural32 (19.8)10 (25.6)1.4 (0.61-3.35) Piped26 (16.0)6 (15.4)1.1 (0.73–1.55)0.755 Mixed8 (4.9)2 (5.1)1.1 (0.22-5.77)Fecal Disposal Toilet20 (12.3)3 (7.7)1 Pit Latrine142 (87.7)36 (92.3)0.6 (0.17–2.10)0.392Current GI Symptoms Asymptomatic45 (27.8)10 (25.6)1 Symptomatic117 (72.2)29 (74.4)1.1 (0.50–2.47)0.787Sought Medical Attention for GI Symptoms (n=146 symptomatic) Yes57 (71.3)9 (28.1)1 No61 (74.4)23 (79.3)3.0 (1.18–7.53)0.014*Other tribes: Langi (13, 6.5%), Alur (5, 2.5%), Lugbara, Muganda, Mukiga, munyankole, munyoro (1 each, 0.5%) Shows analysis of factors associated with intestinal parasitosis among DM patients. *Other tribes: Langi (13, 6.5%), Alur (5, 2.5%), Lugbara, Muganda, Mukiga, munyankole, munyoro (1 each, 0.5%) 4. Discussion In this study, we aimed to determine the prevalence and factors associated with IP among adults with DM attending GRRH. The prevalence of intestinal parasitosis was 19.4%. Entamoeba coli, a non-pathogenic commensal, constituted the majority (89.7%), while the four pathogenic parasites. Hymenolepis nana, Giardia duodenalis, Entamoeba histolytica, and Iodamoeba buetschlii were each identified in one case (2.6%). The presence of Entamoeba coli among the participants indicates fecal-oral contamination and poor sanitation among the participants, increasing the risk of exposure to truly pathogenic parasites. This calls for the need to improve the WASH (Water, Sanitation, and Hygiene) strategy in the communities to reduce the risk of fecal-oral contamination. Our findings are consistent with prior studies, which found the prevalence of intestinal parasites among DM patients at 19.5% in Ethiopia [11], 20.6% in Sudan [17] and 18.7% in Nigeria [13]. However, our study reported a higher prevalence than what was found in Thailand and India, which were 11.31% and 13.6% respectively. [18,19]. The differences in the findings could be explained by the differences in the characteristics of the study populations. The studies with consistent findings were all conducted in sub-Saharan Africa, which is among the regions recognized for having the highest prevalence for IP, hence moreless similar study population. Interestingly, the other studies that reported lower prevalencies were conducted in Asia, which is also among the WHO areas endemic for IP. This could be attributable to differences in health care systems, environmental conditions, behavioral practices, and immunological differences among the participants. The presence of pathogenic intestinal parasitosis in DM immunocompromised patients suggests a risk of increased morbidity and mortality among this population. This is because IP can lead to dehydration, malnutrition, and hospitalization, which can worsen the DM outcomes, such as ketoacidosis and neuropathy. Additionally, the significant burden of IPs among DM patients calls for the need to perform routine screening for these patients, which imposes a cost burden to the health sector, especially in low- and middle-income countries. Our study found that patients who did not seek medical attention for abdominal symptoms were three [3] times more likely to have intestinal parasites. This is consistent with Sisu et al, who found that patients with no history of visit to a dietician had an increased risk of acquiring IP [12]. Despite our study showing no significant association with known risk factors such as: presence of gastrointestinal symptoms, pet ownership, and rural residence, several other studies showed an association with these factors. IP association with the presence of gastrointestinal symptoms was reported in Ghana [12], and Ethiopia [11], an association with pet ownership was noted in Ethiopia [11], and an association with rural residence was reported in Egypt [20]. Other than these factors, several other factors such as poor educational background, poor sanitation and hygiene, inappropriate latrine use, uncontrolled DM, and presence of complications have also been identified [11–13,20,21]. Pet ownership exposes humans to intestinal parasitosis through direct contact, environmental contamination by the pet’s fecal matter, and zoonotic transmission for pets that hunt wild animals. Rural residence stands out as a risk due to an interplay of environmental, behavioral, infrastructural, and socio-economic factors such as open defecation, unprotected wells and rivers, poorly maintained pit latrines, and barefoot walking. 5. Limitations The convenience sampling technique that we used for participant selection poses a risk of bias in the selection and affects the generalizability of our findings. Additionally, our results are not generalizable to the rural population, as more than half of our participants were from the urban population. This urban skew of the sample limits the applicability of our findings to predominantly rural Northern Uganda. We used one stool sample for the diagnosis of intestinal parasites, which reduces sensitivity for detecting intestinal parasitosis, since STHs have intermittent shedding of eggs [22]. This was because our participants were from distant places and could not come to provide stool samples on 3 separate days, and we also had logistical constraints to support the laboratory work for the 3 samples for each patient. We were also not able to perform molecular diagnosis of the intestinal parasites. This was due to logistical constraints and a lack of access. 6. Conclusion The prevalence of intestinal parasitosis was 19.4%. Entamoeba coli, a non-pathogenic commensal, constituted the majority, while the other identified parasites were pathogenic: Hymenolepis nana, Giardia duodenalis, Entamoeba histolytica, and Iodamoeba buetschlii. Our findings suggest that DM patients remain at risk of acquiring IP, which can impact their quality of life. We recommend routine screening for intestinal parasites and prompt treatment to improve the quality of life of patients with DM, continued health education on sanitation and personal hygiene, and future studies using triplicate stool sampling and molecular methods to enhance detection sensitivity. Supporting information S1 Questionnaire English. This is the questionnaire in English. (PDF) S2 Dataset Intestinal parasitosis. This is the dataset for intestinal parasitosis. (XLSX) 31 Oct 2025 Dear Dr. Ngolobe, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== ACADEMIC EDITOR: Please submit your revised manuscript by Dec 15 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Alqeer Aliyo Ali, MSc Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: No Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: No Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: No Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: No Reviewer #2: Yes ********** Reviewer #1: 1. Zero STHI prevalence is a major finding but is not sufficiently contextualized within national deworming or public health programs that may explain this result. 2. The title and abstract emphasize STHIs, yet the study found non this creates a mismatch between stated objectives and actual findings. 3. Reframe the study focus: Given the absence of STHIs, consider repositioning the paper to emphasize intestinal parasitosis broadly among DM patients in Uganda. 4. Sample size justification uses Slovin’s formula, which is simplistic and not ideal for prevalence studies; a more robust epidemiological formula (e.g., Cochran’s) would be preferable. 5. Convenience sampling introduces selection bias and limits generalizability; this limitation is underemphasized. 6. Only one stool sample per participant was analyzed, which significantly reduces sensitivity for detecting STHIs due to intermittent egg shedding. 7. Given that no STHIs were detected, how do you reconcile this with Uganda’s reported STHI prevalence of 5–50% in other regions? 8. The methods section lacks detail on how the Kato-Katz and Odongo-Aginya methods were specifically applied (e.g., number of slides, timing, technician training). 9. No molecular diagnostics (e.g., PCR) were used, despite their known higher sensitivity for helminths like Strongyloides stercoralis. 10. The discussion does not adequately explore why STHIs were absent, especially given Uganda’s reported 5–50% STHI prevalence. 11. Entamoeba coli is mischaracterized as “non-pathogenic normal flora”while generally non-pathogenic, its presence indicates fecal-oral contamination and poor sanitation. 12. Include a limitation paragraph explicitly stating that the inability to perform association analyses due to zero STHI cases is a major constraint. 13. Candida albicans is mentioned incidentally but without clinical context was this considered colonization or infection? 14. Statistical analysis of associated factors is missing despite the aim to identify “factors associated with STHIs,” no inferential analysis could be performed due to zero cases, yet this is not explicitly acknowledged. 15. Was seasonality accounted for? The study ran from October 2024 to March 2025 could dry vs. rainy seasons affect STHI transmission? 16. Ethics approval date discrepancy: Approval was granted in 2024, but an amendment is dated 30/05/2025, which is in the future relative to the current date (October 2025). This needs clarification. 17. Inconsistent data availability statement: The submission form states “All relevant data are within the manuscript,” but the manuscript says “Data are available upon reasonable request.” 18. Overstatement of novelty: The claim that data on STHIs in DM patients in Uganda are “scarce” may be true, but the absence of STHIs limits the novelty of findings. 19. No multivariate analysis was possible, yet the abstract implies assessment of “associated factors” this is misleading. 20. Gastrointestinal symptoms (72.6%) are high, yet only 2% were linked to STHIs this disconnect warrants deeper exploration of alternative causes. 21. Pet ownership (67.7%) is noted but not discussed as a potential risk factor for non-STH parasites (e.g., Giardia, Hymenolepis). 22. Urban vs. rural residence is reported, but no analysis compares parasitic infection rates by residence missed opportunity. 23. Fasting blood sugar levels are high (mean 11.9 mmol/L), indicating poor glycemic control, yet no correlation is attempted with parasite presence. 24. Discuss public health implications of finding pathogenic non-STH parasites (e.g., E. histolytica, Giardia) in immunocompromised DM patients. 25. Reference list includes a 2025 citation (Debash et al., 2025) verify if this is an in-press or ahead-of-print article; otherwise, it may be inaccurate. 26. In light of your findings, do you still believe routine STHI screening is warranted for DM patients in this setting, or should screening focus on all intestinal parasites? Reviewer #2: Thank you editor for providing me this opportunity to review this interesting manuscript. I have completed my review and sending my suggestions and questions for author(s) as follows: 1. Clarify the ethical approval timeline, especially the 2025 amendment date, to avoid confusion or perceived errors. 3. Harmonize the data availability statement across the manuscript and submission form to comply with PLOS ONE policy. 4. Add a subsection in the Discussion on the possible impact of Uganda’s national deworming programs or improved sanitation on STHI reduction. 6. Recommend future studies use triplicate stool sampling and molecular methods to enhance detection sensitivity. 8. Improve methodological transparency: Specify how many Kato-Katz thick smears were prepared per sample and who performed microscopy. 9. Consider subgroup analysis of the 39 parasitized vs. 162 non-parasitized patients to identify risk factors for any intestinal parasite. 10. Revise the title and abstract to reflect the actual findings (e.g., “Absence of Soil-Transmitted Helminths but Presence of Other Intestinal Parasites...”). Questions for author(s) 11. Why was only one stool sample collected per participant, despite WHO recommendations for multiple samples to improve sensitivity? 12. Were any quality control measures (e.g., duplicate readings, expert validation) implemented during microscopic examination? 13. How was “uncontrolled diabetes” defined was it based solely on fasting blood sugar, or were HbA1c levels also considered? 14. What is the clinical significance of detecting Candida albicans in stool was this considered contamination, colonization, or invasive infection? 15. Did you consider analyzing associations between parasite presence and diabetes complications (e.g., neuropathy, retinopathy)? 16. How generalizable are your findings to rural Ugandan populations, given that over half your sample was urban? 9. Were participants screened for HIV or other immunosuppressive conditions that might influence parasite susceptibility? ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 14 Nov 2025 On behalf of the authors’ team for our study “Prevalence and factors associated with Soil-Transmitted Helminths Infections among adults with diabetes mellitus attending a tertiary care facility in Northern Uganda: A hospital-based cross-sectional study”, we sincerely thank the reviewers for the insightful and constructive feedback on our manuscript. The comments we received have significantly strengthened the clarity, rigor, and impact of our work. In the table below, we provided a point-by-point response to each comment we received, explaining the revisions made and indicating where the changes were incorporated in the revised manuscript. We believe these changes address all concerns and enhance the paper’s contribution to the field. We look forward to your kind feedback. Table showing response to reviewers’ comments S/No COMMENT RESPONSE PAGE Number (As in track change file) ACADEMIC EDITOR’S COMMENTS 1 The authors should reframe the title and abstract to reflect the broader focus on intestinal parasitosis The title and abstract have been reframed Page 1 and 2 2. Provide a more robust justification for the sampling strategy We used convenience sampling technique because; Most of the patients attending the clinic were adults, and a number of them were not willing to provide a stool sample for the study, claiming that it was uncomfortable and that they had no urge to pass stool. Additionally, we had limited resources to sustain a probability sampling technique, given the limited time we had for data collection. In light of the above reasons, convenient sampling technique was adapted. Pg 7 3 transparently address methodological limitations such as single stool sampling and lack of molecular diagnostics We collected a single stool sample because we only had the chance to interface with participants as they came for their routine Diabetic care review, which happens at a 1-month interval, and we could therefore not access them easily to provide the 3 separate samples within a 2 to 3 day interval as recommended by WHO. Also, our participants were from distant places and could not come to provide stool samples on 3 separate days, due to transportation constraints. We also had logistical constraints to support the laboratory work for the 3 samples for each patient Pg 24 4. Additionally, the ethical approval timeline We received initial approval on 24/09/2024 and started data collection in October 2024. We then made amendments, and the amendment approval was given on 30/05/2025 Pg 8 5. Data availability statement must be clarified and harmonized to meet journal standards We have addressed this by emphasizing that; All relevant data are within the manuscript and its supporting information files. Data are available upon reasonable request from the first author Pg 27 REVIEWER 1 COMMENTS 1. Zero STHI prevalence is a major finding but is not sufficiently contextualized within national deworming or public health programs that may explain this result. We have considered intestinal parasitosis instead of STHIs, as guided by the academic editor. This change has been embraced throughout the manuscript. 2. The title and abstract emphasize STHIs, yet the study found non this creates a mismatch between stated objectives and actual findings. The title and abstract have been modified to emphasize intestinal parasitosis, and the objectives and findings have also been restructured in line with intestinal parasitosis Title page, Pg 1,2, 3. Reframe the study focus: Given the absence of STHIs, consider repositioning the paper to emphasize intestinal parasitosis broadly among DM patients in Uganda. We have reframed the study to focus on intestinal parasitosis Throughout the manuscript 4. Sample size justification uses Slovin’s formula, which is simplistic and not ideal for prevalence studies; a more robust epidemiological formula (e.g., Cochran’s) would be preferable. We've adjusted to use the Cochran formula, which gives us a sample size of 267 participants and a response rate of 75.3% (n=201/267) Pg 7 5. Convenience sampling introduces selection bias and limits generalizability; this limitation is underemphasized. We have included this limitation in our limitations section Pg 24 6. Only one stool sample per participant was analyzed, which significantly reduces sensitivity for detecting STHIs due to intermittent egg shedding. This was because we only had the chance to interface with participants as they came for their routine Diabetic care review, which happens at a 1-month interval, and we could therefore not access them easily to provide the 3 separate samples within a 2 to 3 day interval as recommended by WHO. Also, our participants were from distant places and could not come to provide stool samples on 3 separate days, due to transportation constraints. We also had logistical constraints to support the laboratory work for the 3 samples for each patient Pg 24 7. Given that no STHIs were detected, how do you reconcile this with Uganda’s reported STHI prevalence of 5–50% in other regions? We have reframed our manuscript to focus on intestinal parasites rather than STHIs. With the reframing, our study now emphasizes the presence of intestinal parasitosis, at a prevalence of 19.4% unlike the initial absence of STHIs. Pg 16 8. The methods section lacks detail on how the Kato-Katz and Odongo-Aginya methods were specifically applied (e.g., number of slides, timing, technician training). This has been addressed. Two thick smears were prepared, and analysis was done within a 4-hour interval from the time of sample collection. The stool analysis was performed by 1 laboratory technician and 1 professor of parasitology. Pg 7 9. No molecular diagnostics (e.g., PCR) were used, despite their known higher sensitivity for helminths like Strongyloides stercoralis. This was not possible due to limited logistics. No PCR tests were being done in the laboratory that analyzed our samples, and additionally, we had limited funds to support analysis elsewhere. Pg 24 10. The discussion does not adequately explore why STHIs were absent, especially given Uganda’s reported 5–50% STHI prevalence. The discussion has been reframed to focus on intestinal parasitosis and not STHIs, since they were absent Pg 19-23 11. Entamoeba coli is mischaracterized as “non-pathogenic normal flora,” while generally non-pathogenic, its presence indicates fecal-oral contamination and poor sanitation. We have re-characterized it under pathogenic parasites and discussed the need to embrace the WASH strategy to mitigate its transmission, since its presence indicates ongoing fecal-oral contamination. Abstract and Pg 19 12. Include a limitation paragraph explicitly stating that the inability to perform association analyses due to zero STHI cases is a major constraint. Since we’ve reframed our manuscript to focus on intestinal parasitosis, and we found intestinal parasitosis in 19.4% of the participants, we have performed association analyses Pg 17-19 13. Candida albicans is mentioned incidentally but without a clinical context. Was this considered colonization or infection? It was considered a colonization 14. Statistical analysis of associated factors is missing despite the aim to identify “factors associated with STHIs,” no inferential analysis could be performed due to zero cases, yet this is not explicitly acknowledged. We’ve reframed our manuscript to focus on intestinal parasitosis, and since we found intestinal parasitosis, inferential analysis has been performed Pg 17-19 15. Was seasonality accounted for? The study ran from October 2024 to March 2025. Could dry vs. rainy seasons affect STHI transmission? Yes, seasons affect STHI transmission, with the transmission being higher during rainy seasons due to increased contamination from running water and latrine overflows, and favorable conditions of breeding for the vectors. The wet season in our study area ranges from April to November, and the dry season ranges from November to March. However, we couldn't halt data collection until the wet season begins, as we would not meet the timeline that had been given to us to conduct the study. 16. Ethics approval date discrepancy: Approval was granted in 2024, but an amendment is dated 30/05/2025, which is in the future relative to the current date (October 2025). This needs clarification. We received initial approval on 29/09/2024 and started data collection in October 2024. We then made amendments, and the amendment approval was given on 30/05/2025. Pg 8 17. Inconsistent data availability statement: The submission form states “All relevant data are within the manuscript,” but the manuscript says “Data are available upon reasonable request. This has been corrected, emphasizing that: All relevant data are within the manuscript and its supporting information files. Data are available upon reasonable request from the first author Pg 27 18. Overstatement of novelty: The claim that data on STHIs in DM patients in Uganda are “scarce” may be true, but the absence of STHIs limits the novelty of findings To address this, our manuscript has been reframed to focus on intestinal parasitosis rather than STHIs Throughout the manuscript 19. No multivariate analysis was possible, yet the abstract implies assessment of “associated factors.” this is misleading. With a focus on intestinal parasitosis, factor analysis was possible, and it has been performed Pg 17-19 20. Gastrointestinal symptoms (72.6%) are high, yet only 2% were linked to STHIs this disconnect warrants deeper exploration of alternative causes. We agree to this. 21. Pet ownership (67.7%) is noted but not discussed as a potential risk factor for non-STH parasites (e.g., Giardia, Hymenolepis). We have discussed pet ownership as a risk factor for intestinal parasitosis. Pg 22 22. Urban vs. rural residence is reported, but no analysis compares parasitic infection rates by residence, a missed opportunity. We have performed an analysis to compare parasitic infection by residence and found no association Pg 17-19 23. Fasting blood sugar levels are high (mean 11.9 mmol/L), indicating poor glycemic control, yet no correlation is attempted with parasite presence. We have performed a correlation for Fasting Blood sugar with intestinal parasites, though it wasn’t found to be significant (p=0.256) Pg 17 24. Discuss public health implications of finding pathogenic non-STH parasites (e.g., E. histolytica, Giardia) in immunocompromised DM patients. This has been discussed, and we have emphasized the risk of worsening morbidity and mortality in this population. Additionally, implementing screening for these patients generates a direct cost impact on the health sector. Pg 21 25. Reference list includes a 2025 citation (Debash et al., 2025). Verify if this is an in-press or ahead-of-print article; otherwise, it may be inaccurate. We’ve verified and found that it’s a valid article, published in the BMC Infectious Diseases journal (https://doi.org/10.1186/s12879-025-10441-4) 26. In light of your findings, do you still believe routine STHI screening is warranted for DM patients in this setting, or should screening focus on all intestinal parasites? Screening should focus on all intestinal parasites and not only STHI as previously thought Pg 25 REVIEWER 2 COMMENTS 1. Clarify the ethical approval timeline, especially the 2025 amendment date, to avoid confusion or perceived errors. We received initial approval on 29/09/2024 and started data collection in October 2024. We then made amendments, and the amendment approval was given on 30/05/2025 Pg 8 2. Harmonize the data availability statement across the manuscript and submission form to comply with PLOS ONE policy. We have harmonized this emphasizing that; All relevant data are within the manuscript and its supporting information files. Data are available upon reasonable request from the first author Pg 27 3. Add a subsection in the Discussion on the possible impact of Uganda’s national deworming programs or improved sanitation on STHI reduction. With a focus on intestinal parasitosis, our study revealed evidence of poor sanitation (ongoing fecal oral contamination) by the presence of Entamoeba coli. We therefore recommended enhancement of the WASH strategy and screening as preventive strategies to combat this ongoing spread. Pg 19, 25 4. Recommend future studies use triplicate stool sampling and molecular methods to enhance detection sensitivity. This recommendation has been included Pg 25 5. Improve methodological transparency: Specify how many Kato-Katz thick smears were prepared per sample and who performed microscopy. This has been addressed. Two (2) smears were prepared by a laboratory technician and a parasitology professor. Pg 7 6. Consider subgroup analysis of the 39 parasitized vs. 162 non-parasitized patients to identify risk factors for any intestinal parasite. We have performed this subgroup analysis. Pg 17-19 7. Revise the title and abstract to reflect the actual findings (e.g., “Absence of Soil-Transmitted Helminths but Presence of Other Intestinal Parasites...”). The title and abstract have been revised Title page, Pg 1,2 8. Why was only one stool sample collected per participant, despite WHO recommendations for multiple samples to improve sensitivity? We obtained a single stool sample because patients come to the clinic every 1 month and could not meet the 3-day WHO-recommended interval between stool sample collection. Additionally, most of our participants resided in locations distant from our study site and couldn’t come on 3 separate days to provide samples. Furthermore, there were limited funds to facilitate the laboratory technician to analyze the 3 samples. We did not have access to any molecular diagnostics, since they weren’t available in the laboratory at our study site, and there were limited funds to transport and facilitate molecular diagnosis elsewhere. 9. Were any quality control measures (e.g., duplicate readings, expert validation) implemented during microscopic examination? Quality control measures were implemented. Stool samples that had similar identification numbers were not considered for analysis to avoid duplicates. Every parasite that was not clear to the laboratory technician was proofread and confirmed by the professor of parasitology. 10. How was “uncontrolled diabetes” defined was it based solely on fasting blood sugar, or were HbA1c levels also considered? Uncontrolled diabetes was defined based on fasting blood sugar, because we could not perform HbA1c, since it was absent at the study site, and needed funds to be done elsewhere, which we didn’t have, as the study was not funded. 11. What is the clinical significance of detecting Candida albicans in stool? Was this considered contamination, colonization, or invasive infection? There is no clinical significance of finding Candida in stool. We considered it a contamination, and for clarity, we have removed Candida from our results. All through the manuscript. 12. Did you consider analyzing associations between parasite presence and diabetes complications (e.g., neuropathy, retinopathy)? Analysis of associations has been done, and we found no association of intestinal parasites with DM complications (p=0.900) Pg 17-19 13. How generalizable are your findings to rural Ugandan populations, given that over half your sample was urban? Our findings are not generalizable to the rural population. We have included this in our limitations 14. Were participants screened for HIV or other immunosuppressive conditions that might influence parasite susceptibility? No, we did not screen the participants for HIV or other immunosuppressive conditions Submitted filename: Response to Reviewers.docx 25 Nov 2025 Dear Dr. Ngolobe, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== The authors have been highly responsive and have successfully reframed their paper, which is a significant improvement. The requested changes are not major but are essential for the manuscript's scientific accuracy, clarity, and focus. The authors are commended for their thorough revisions and for refocusing the manuscript on intestinal parasitosis, which has significantly strengthened the paper. However, minor revisions are required to address lingering issues related to the characterization of Entamoeba coli , the focus of the discussion, and minor inconsistencies in dates and grammar. Please carefully review the points listed above and submit a final version for editorial consideration. Here are the key issues that should be addressed in a final round of revisions:

1. Abstract - Grammar and Clarity

The abstract contains several grammatical errors and awkward phrases that affect readability.Example: "Descriptive and inferential statistics were performed to assess the prevalence..." → This is redundant. Suggest: "Descriptive statistics and logistic regression were used to determine the prevalence and identify factors associated with IP."Recommendation: A thorough proofread of the abstract is needed to improve flow and correct minor grammatical errors. The abstract contains several grammatical errors and awkward phrases that affect readability. The abstract contains several grammatical errors and awkward phrases that affect readability. Example: "Descriptive and inferential statistics were performed to assess the prevalence..." → This is redundant. Suggest: "Descriptive statistics and logistic regression were used to determine the prevalence and identify factors associated with IP." Example: "Descriptive and inferential statistics were performed to assess the prevalence..." → This is redundant. Suggest: "Descriptive statistics and logistic regression were used to determine the prevalence and identify factors associated with IP." Recommendation: A thorough proofread of the abstract is needed to improve flow and correct minor grammatical errors. Recommendation: A thorough proofread of the abstract is needed to improve flow and correct minor grammatical errors.

2. Characterization of Entamoeba coli

The authors have correctly noted that the presence of E. coli indicates fecal-oral contamination. However, labeling it as a "pathogenic" parasite in the Abstract (line 25) and Results (line 153) is scientifically inaccurate.Entamoeba coli is widely recognized as a non-pathogenic commensal. Its significance lies in its role as a marker of poor sanitation, not as a cause of disease.Recommendation: Consistently refer to E. coli as a "non-pathogenic intestinal protozoan" or "commensal" throughout the manuscript. The public health message remains strong: its presence indicates a risk of exposure to truly pathogenic parasites. The authors have correctly noted that the presence of E. coli indicates fecal-oral contamination. However, labeling it as a "pathogenic" parasite in the Abstract (line 25) and Results (line 153) is scientifically inaccurate. The authors have correctly noted that the presence of E. coli indicates fecal-oral contamination. However, labeling it as a "pathogenic" parasite in the Abstract (line 25) and Results (line 153) is scientifically inaccurate. Entamoeba coli is widely recognized as a non-pathogenic commensal. Its significance lies in its role as a marker of poor sanitation, not as a cause of disease. Entamoeba coli is widely recognized as a non-pathogenic commensal. Its significance lies in its role as a marker of poor sanitation, not as a cause of disease. Recommendation: Consistently refer to E. coli as a "non-pathogenic intestinal protozoan" or "commensal" throughout the manuscript. The public health message remains strong: its presence indicates a risk of exposure to truly pathogenic parasites. Recommendation: Consistently refer to E. coli as a "non-pathogenic intestinal protozoan" or "commensal" throughout the manuscript. The public health message remains strong: its presence indicates a risk of exposure to truly pathogenic parasites.

3. Discussion Section - Lingering STH Content

The Discussion still contains a long paragraph (pages 58-59, lines 242-261) discussing factors associated with STH and Strongyloides stercoralis , which were not found in this study.This section feels out of place and dilutes the new focus on the intestinal parasites that were actually found.Recommendation: Remove or significantly shorten this paragraph. The discussion should focus on interpreting the findings of this study (e.g., the high prevalence of E. coli , the single significant risk factor, the implications of finding Giardia and E. histolytica in a diabetic population). The Discussion still contains a long paragraph (pages 58-59, lines 242-261) discussing factors associated with STH and Strongyloides stercoralis , which were not found in this study. The Discussion still contains a long paragraph (pages 58-59, lines 242-261) discussing factors associated with STH and Strongyloides stercoralis , which were not found in this study. This section feels out of place and dilutes the new focus on the intestinal parasites that were actually found. This section feels out of place and dilutes the new focus on the intestinal parasites that were actually found. Recommendation: Remove or significantly shorten this paragraph. The discussion should focus on interpreting the findings of this study (e.g., the high prevalence of E. coli , the single significant risk factor, the implications of finding Giardia and E. histolytica in a diabetic population). Recommendation: Remove or significantly shorten this paragraph. The discussion should focus on interpreting the findings of this study (e.g., the high prevalence of E. coli , the single significant risk factor, the implications of finding Giardia and E. histolytica in a diabetic population).

4. Ethics Statement - Date Inconsistency

In the manuscript (page 18, line 101) and the ethics statement (page 7), the initial approval date is listed as "29/09/2025". This is a clear typo, as data collection started in October 2024.The response to reviewers correctly states it as "29/09/2024".Recommendation: Correct this date to "29/09/2024" in the manuscript's methods section and ethics statement to avoid confusion and maintain credibility. In the manuscript (page 18, line 101) and the ethics statement (page 7), the initial approval date is listed as "29/09/2025". This is a clear typo, as data collection started in October 2024. In the manuscript (page 18, line 101) and the ethics statement (page 7), the initial approval date is listed as "29/09/2025". This is a clear typo, as data collection started in October 2024. The response to reviewers correctly states it as "29/09/2024". The response to reviewers correctly states it as "29/09/2024". Recommendation: Correct this date to "29/09/2024" in the manuscript's methods section and ethics statement to avoid confusion and maintain credibility. Recommendation: Correct this date to "29/09/2024" in the manuscript's methods section and ethics statement to avoid confusion and maintain credibility.

5. Limitations Section - Emphasis on Generalizability

The authors rightly note that their findings are not generalizable to the rural population. This is a crucial limitation.Recommendation: Consider strengthening this point by explicitly stating that the urban skew of the sample limits the applicability of the findings to predominantly rural Northern Uganda. The authors rightly note that their findings are not generalizable to the rural population. This is a crucial limitation. The authors rightly note that their findings are not generalizable to the rural population. This is a crucial limitation. Recommendation: Consider strengthening this point by explicitly stating that the urban skew of the sample limits the applicability of the findings to predominantly rural Northern Uganda. Recommendation: Consider strengthening this point by explicitly stating that the urban skew of the sample limits the applicability of the findings to predominantly rural Northern Uganda. ============================== Please submit your revised manuscript by Jan 09 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Alqeer Aliyo Ali, MSc Academic Editor PLOS ONE Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: The author(s) have revises the manuscript and responded my queries accordingly. Therefore, the manuscript now acceptable. Reviewer #2: I satisfied with the author corrections as well as the changes he/her made. I recommend the article should be considered for publication. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 26 Nov 2025 RESPONSE TO REVIEWERS II On behalf of the authors’ team for our study “Prevalence and factors associated with Intestinal parasitosis among adults with diabetes mellitus attending a tertiary care facility in Northern Uganda: A hospital-based cross-sectional study”, we sincerely thank the reviewers for the additional feedback and comments on our manuscript. The comments we received have significantly improved the clarity, rigor, and scientific impact of our work. In the table below, we provided a point-by-point response to each comment we received, explaining the revisions made and indicating where the changes were incorporated in the revised manuscript. We believe these changes address all concerns and enhance the paper’s contribution to the field. We look forward to your kind feedback. S/No Comment Response Page in mark-up copy 1 The abstract contains several grammatical errors and awkward phrases that affect readability. This has been addressed Page 1 and 2 2. Consistently refer to E. coli as a "non-pathogenic intestinal protozoan" or "commensal" throughout the manuscript. We have corrected this Line 35 (Page 2), Line 180 (Page 14) Line 206 (Page 17) Line 265 (Page 20) 3. The Discussion still contains a long paragraph (pages 58-59, lines 242-261) discussing factors associated with STH and Strongyloides stercoralis, which were not found in this study This has been rectified. 4. In the manuscript (page 18, line 101) and the ethics statement (page 7), the initial approval date is listed as "29/09/2025". This is a clear typo, as data collection started in October 2024. We have corrected this Line 122 (Page 6) in the manuscript and also in the ethical statement. 5. Consider strengthening this point by explicitly stating that the urban skew of the sample limits the applicability of the findings to predominantly rural Northern Uganda. We have addressed this Line 256 (Page 20) Submitted filename: RESPONSE_TO_REVIEWERS_auresp_2.docx 28 Nov 2025 Prevalence and factors associated with Intestinal parasitosis among adults with diabetes mellitus attending a tertiary care facility in Northern Uganda: A hospital-based cross-sectional study PONE-D-25-53019R2 Dear Dr. Ngolobe, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Alqeer Aliyo Ali, MSc Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: PONE-D-25-53019R2 PLOS One Dear Dr. Ngolobe, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Mr. Alqeer Aliyo Ali Academic Editor PLOS One